Private Equity

Private equity firm Sole Source Capital acquires cybersecurity provider Brite, signaling a major 'buy-and-build' play in a booming, fragmented market.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

The insurance giant landed a major credit facility, calming investor nerves and doubling down on its fast-growing pharmacy and healthcare services arm.

Leasing begins at The Orchard, a new luxury giant in Long Island City. But as it sets records, it also raises questions about the neighborhood's future.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a $30M Series A from Five Elms Capital, Trybe is set to revolutionize the spa and leisure industry with AI, challenging legacy systems worldwide.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

As the ISS era ends, Mitsubishi Corporation's major investment in Starlab Space secures Japan's future in orbit and heats up the commercial space race.

A new podcast season peeks inside the minds of the ultra-wealthy as they navigate the complex, often existential, questions that follow massive success.

As a foundational CFO steps down, XOMA Royalty brings in biotech veteran Jeffrey Trigilio to enhance its dealmaking strategy and expand its royalty portfolio.

As FuelCell Energy eyes larger global projects, it hires a legal expert known for scaling power giants, signaling a strategic shift to execution.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

Uniper secures 500,000 tons of certified green ammonia from India's AM Green, forging a new energy axis and fueling Europe's industrial decarbonization.

A new joint venture will build a massive solar tracker factory in Saudi Arabia, aiming to accelerate the Kingdom's green energy goals and create 2,000 jobs.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

Following its acquisition by education giant Cogna, Vasta Platform is leaving the US stock market, signaling a major shift in Brazil's EdTech landscape.